Clinical recommendations for the use of everolimus in heart transplantation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Schuler, 1997, SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo, Transplantation, 64, 36, 10.1097/00007890-199707150-00008
2001
2006
Pascual, 2006, Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions, Transplant Rev, 20, 1, 10.1016/j.trre.2005.10.005
Vitko, 2005, Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients, Am J Transplant, 5, 2521, 10.1111/j.1600-6143.2005.01063.x
Lorber, 2005, Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study, Transplantation, 80, 244, 10.1097/01.TP.0000164352.65613.24
Eisen, 2006, The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation, Transplantation, 82, S13, 10.1097/01.tp.0000243152.19789.0e
Kauffman, 2005, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies, Transplantation, 80, 883, 10.1097/01.TP.0000184006.43152.8D
Eisen, 2003, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients, N Engl J Med, 349, 847, 10.1056/NEJMoa022171
Kobashigawa, 2006, Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report, Am J Transplant, 6, 1377, 10.1111/j.1600-6143.2006.01290.x
Delgado, 2009, The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation, Transplant Rev (Orlando), 23, 69, 10.1016/j.trre.2009.01.002
Vigano, 2007, Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis, J Heart Lung Transplant, 26, 584, 10.1016/j.healun.2007.03.005
Keogh, 2004, Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial, Circulation, 110, 2694, 10.1161/01.CIR.0000136812.90177.94
Keogh, 2007, Sirolimus vs Azathioprine from the time of heart transplantation: 65 month followup for vascular (MACE) and malignant events, J Heart Lung Transplant, 26, S231, 10.1016/j.healun.2006.11.498
Dengler, 2008, Concentration-controlled everolimus versus MMF in de novo heart transplant patients: Incidence of CMV infection at 12 months post-transplant in a randomized trial, J Heart Lung Transplant, 27, S65, 10.1016/j.healun.2007.11.020
Lehmkuhl, 2008, Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in de novo cardiac transplant recipients, J Heart Lung Transplant, 27, S65, 10.1016/j.healun.2007.11.019
Kobashigawa, 1998, A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators, Transplantation, 66, 507, 10.1097/00007890-199808270-00016
Hosenpud, 2001, Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry, TransplantatAion, 72, 1662, 10.1097/00007890-200111270-00015
Eisen, 2005, Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients, J Heart Lung Transplant, 24, 517, 10.1016/j.healun.2005.02.002
Crespo-Leiro, 2008, Malignancy after heart transplantation: incidence, prognosis and risk factors, Am J Transplant, 8, 1031, 10.1111/j.1600-6143.2008.02196.x
Taylor, 2008, Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth Official Adult Heart Transplant Report—2008, J Heart Lung Transplant, 27, 943, 10.1016/j.healun.2008.06.017
Hojo, 1999, Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, 397, 530, 10.1038/17401
Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128
Gutierrez-dalmau, 2006, Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review, Drugs, 67, 1167, 10.2165/00003495-200767080-00006
Dantal, 2005, Immunosuppressive drugs and the risk of cancer after organ transplantation, N Engl J Med, 352, 1371, 10.1056/NEJMe058018
Jensen, 1996, Chromosome aberrations in human cells following treatment with imuran. Preliminary report, Acta Med Scand, 179, 249, 10.1111/j.0954-6820.1966.tb05454.x
O'Donovan, 2005, Azathioprine and UVA light generate mutagenic oxidative DNA damage, Science, 309, 1871, 10.1126/science.1114233
Herrero, 2005, Nonmelanoma skin cancer after liver transplantation. Study of risk factors, Liver Transpl, 11, 1100, 10.1002/lt.20525
Robson, 2005, Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil, Am J Transplant, 5, 2954, 10.1111/j.1600-6143.2005.01125.x
Birkeland, 2003, Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?, Transplantation, 76, 984, 10.1097/01.TP.0000085602.22498.CF
Caillard, 2005, Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression, Transplantation, 80, 1233, 10.1097/01.tp.0000179639.98338.39
Mathew, 2004, Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies, Clin Transplant, 18, 446, 10.1111/j.1399-0012.2004.00188.x
Campistol, 2006, Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation, J Am Soc Nephrol, 17, 581, 10.1681/ASN.2005090993
Schena, 2009, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial, Transplantation, 87, 233, 10.1097/TP.0b013e3181927a41
Pascual, 2005, Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral in de novo kidney transplant recipients: 24 months analysis, Am J Transplant, 5, 414
Rothenburger, 2007, Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference, J Heart Lung Transplant, 26, 305, 10.1016/j.healun.2007.01.010
Zuckermann, 2008, Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation, J Heart Lung Transplant, 27, 141, 10.1016/j.healun.2007.08.014
Lehmkuhl, 2005, Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure, Transplant Proc, 37, 4145, 10.1016/j.transproceed.2005.10.005
Gonzalez-Vilchez, 2008, Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure, J Heart Lung Transplant, 27, 1135, 10.1016/j.healun.2008.07.020
Raichlin, 2007, Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation, Circulation, 116, 2726, 10.1161/CIRCULATIONAHA.107.692996
Ojo, 2003, Chronic renal failure after transplantation of a nonrenal organ, N Engl J Med, 349, 931, 10.1056/NEJMoa021744
Schweiger, 2006, Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients, Transpl Immunol, 16, 46, 10.1016/j.trim.2006.02.001
Fuchs, 2005, The role of everolimus in the improvement of renal function in heart transplant recipients, Transplant Int, 18, PO094
Snell, 2001, Rescue therapy: a role for sirolimus in lung and heart transplant recipients, Transplant Proc, 33, 1084, 10.1016/S0041-1345(00)02426-X
Ross, 2007, Reduction of cyclosporine dose in maintenance cardiac transplant recipients after conversion from MMF/AZA to everolimus: 12-month results from a pilot study, Transpl Int, 20, 94
Trosch, 2004, First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation, Thorac Cardiovasc Surg, 52, 163, 10.1055/s-2004-820880
Moro Lopez, 2009, Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime, Transplantation, 87, 538, 10.1097/TP.0b013e31819452ce
Rothenburger, 2006, Calcineurin inhibitor-free immunosuppression using everolimus in maintenance heart transplant recipients-9 months follow-up, Transplantation, 82, 553, 10.1097/00007890-200607152-01446
Hunt, 2005, Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation, J Heart Lung Transplant, 24, 1863, 10.1016/j.healun.2005.02.018
Bestetti, 2006, Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up, Transplantation, 81, 692, 10.1097/01.tp.0000177644.45192.a3
Cabezon, 2005, Sirolimus improves renal function in cardiac transplantation, Transplant Proc, 37, 1546, 10.1016/j.transproceed.2005.02.006
De Meester, 2005, Preservation of renal function after heart transplantation: initial single-center experience with sirolimus, Transplant Proc, 37, 1835, 10.1016/j.transproceed.2005.02.090
Groetzner, 2004, Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure, J Heart Lung Transplant, 23, 770, 10.1016/S1053-2498(03)00212-2
Groetzner, 2004, Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure, Transplantation, 77, 568, 10.1097/01.TP.0000103740.98095.14
Kushwaha, 2005, Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity, J Heart Lung Transplant, 24, 2129, 10.1016/j.healun.2005.08.015
Lyster, 2004, Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation, Transplant Proc, 36, 3167, 10.1016/j.transproceed.2004.10.062
Groetzner, 2004, Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients, Eur J Cardiothorac Surg, 25, 333, 10.1016/j.ejcts.2003.11.030
Gleissner, 2006, Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy, Am J Transplant, 6, 2750, 10.1111/j.1600-6143.2006.01527.x
Rothenburger, 2007, Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up, J Heart Lung Transplant, 26, 250, 10.1016/j.healun.2007.01.017
Delgado, 2005, Sirolimus (SRL) in heart transplantation: preliminary results of a multicenter registry in Spain (Rapacor study), Am J Transplant, 5, S172
Zakliczynski, 2003, Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation, Transplant Proc, 35, 2331, 10.1016/S0041-1345(03)00772-3
Fernandez-Valls, 2005, Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center, Transplant Proc, 37, 4021, 10.1016/j.transproceed.2005.09.152
Mancini, 2003, Use of rapamycin slows progression of cardiac transplantation vasculopathy, Circulation, 108, 48, 10.1161/01.CIR.0000070421.38604.2B
Segovia, 2004, Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study, J Heart Lung Transplant, 23, S51, 10.1016/j.healun.2003.11.030
Crespo Leiro, 2007, Conferencia de Consenso de los Grupos Españoles de Trasplante Cardiaco, Rev Esp Cardiol, 7, 4B
Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9
Fernandez, 2006, Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia, Transplant Proc, 38, 2453, 10.1016/j.transproceed.2006.08.016
de fijter, 2007, Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation, Nephrol Dial Transplant, 22, i23, 10.1093/ndt/gfm086
Campistol, 2004, Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma, Transplantation, 77, 760, 10.1097/01.TP.0000115344.18025.0B
Stallone, 2005, Sirolimus for Kaposi's sarcoma in renal-transplant recipients, N Engl J Med, 352, 1317, 10.1056/NEJMoa042831
Gutierrez-Dalmau, 2005, Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma, Transplant Proc, 37, 3836, 10.1016/j.transproceed.2005.10.076
Lebbe, 2006, Sirolimus conversion for patients with posttransplant Kaposi's sarcoma, Am J Transplant, 6, 2164, 10.1111/j.1600-6143.2006.01412.x
Campistol, 2007, Kaposi's sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors, Nephrol Dial Transplant, 22, i17, 10.1093/ndt/gfm089
Garcia, 2003, Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment, Transpl Int, 16, 202, 10.1111/j.1432-2277.2003.tb00287.x
Cullis, 2006, Sirolimus-induced remission of posttransplantation lymphoproliferative disorder, Am J Kidney Dis, 47, e67, 10.1053/j.ajkd.2006.01.029
Pascual, 2007, Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors, Nephrol Dial Transplant, 22, i27, 10.1093/ndt/gfm088
Elsharkawi, 2005, Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil, Transplantation, 79, 855, 10.1097/01.TP.0000154913.88193.FF
Stippel, 2005, Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation, Transplant Proc, 37, 2185, 10.1016/j.transproceed.2005.03.013
Gomez-Camarero, 2007, Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms, Transplantation, 84, 786, 10.1097/01.tp.0000280549.93403.dd
Starling, 2004, Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling, Am J Transplant, 4, 2126, 10.1046/j.1600-6143.2004.00601.x
Lehmkuhl, 2007, Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients, J Heart Lung Transplant, 26, 700, 10.1016/j.healun.2007.02.008
Bocchi, 2006, Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting, Transplant Proc, 38, 937, 10.1016/j.transproceed.2006.02.049
Ruygrok, 2003, Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression, J Heart Lung Transplant, 22, 1276, 10.1016/S1053-2498(02)01239-1
Raichlin, 2007, Sirolimus as Primary Immunosuppression Prevents Progression of Cardiac Allograft Vasculopathy: A 3-D IVUS Study, J Heart Lung Transplant, 26, S69, 10.1016/j.healun.2006.11.039
Campistol, 2007, Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance, Nephrol Dial Transplant, 22, i36, 10.1093/ndt/gfm090
Brandhorst, 2008, Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor, Ther Drug Monit, 30, 113, 10.1097/FTD.0b013e318161a335
Hummel, 2005, Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference, J Heart Lung Transplant, 24, S196, 10.1016/j.healun.2005.01.010
Brignol, 2001, High-throughput semiautomated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD001) and cyclosporine A (CsA) in whole blood, Rapid Commun Mass Spectrom, 15, 898, 10.1002/rcm.323
Lehmkuhl, 2008, Hospitalization days due to Major Cardiac Events (MACE) in de novo heart transplant recipients: data from a 12-month, multicenter, randomized trial of everolimus versus MMF, J Heart Lung Transplant, 27, S228, 10.1016/j.healun.2007.11.479
Vermes, 2008, More adverse events leading to drug adjustment/interruption in the presence of MMF-vs. everolimus-based immunosuppresion in de novo heart transplant patients, J Heart Lung Transplant, 27, S227, 10.1016/j.healun.2007.11.478
Bellosta, 2006, Everolimus affects cholesterol homeostasis in macrophages
Pascual, 2006, Everolimus in clinical practice-renal transplantation, Nephrol Dial Transplant, 21, iii18, 10.1093/ndt/gfl300
Keogh, 2000, Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation, J Heart Lung Transplant, 19, 529, 10.1016/S1053-2498(00)00077-2
Wenke, 2003, Simvastatin initiated early after heart transplantation: 8-year prospective experience, Circulation, 107, 93, 10.1161/01.CIR.0000043241.32523.EE
Weis, 2001, Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation, J Am Coll Cardiol, 38, 814, 10.1016/S0735-1097(01)01430-9
Kobashigawa, 2005, Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients, J Heart Lung Transplant, 24, 1736, 10.1016/j.healun.2005.02.009
Gregory, 2001, Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts, Transplantation, 72, 989, 10.1097/00007890-200109270-00002
Ferri, 2008, Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression, Mol Pharmacol, 74, 114, 10.1124/mol.108.046045
Aliabadi, 2008, Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation, Transplantation, 86, 1771, 10.1097/TP.0b013e3181910eb2
Moro, 2007, Ezetimibe in heart transplantation: initial experience, Transplant Proc, 39, 2389, 10.1016/j.transproceed.2007.06.043
Crespo-Leiro, 2008, The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation, Transplant Proc, 40, 3060, 10.1016/j.transproceed.2008.09.007
Oroszlan, 2008, Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant, J Heart Lung Transplant, 27, 1311, 10.1016/j.healun.2008.08.013
Wilasrusmee, 2003, Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction, Clin Transplant, 17, 6, 10.1034/j.1399-0012.17.s9.1.x
Yatscoff, 1993, Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro, Clin Biochem, 26, 409, 10.1016/0009-9120(93)90118-P
Huber, 2007, Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis, Kidney Int, 71, 771, 10.1038/sj.ki.5002112
Kuppahally, 2006, Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients, Am J Transplant, 6, 986, 10.1111/j.1600-6143.2006.01282.x
Arizon, 2007, Wound healing in de novo recipients of cardiac allografts: everolimus-based immunosuppression versus MMF in combination with cyclosporine, Transpl Int, 20, 95
Fuchs, 2005, Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema, Transplantation, 79, 981, 10.1097/00007890-200504270-00020
Zuckermann, 2005, Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna, J Heart Lung Transplant, 24, S206, 10.1016/j.healun.2005.01.021
Delgado, 2006, Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients, J Heart Lung Transplant, 25, 1171, 10.1016/j.healun.2006.05.013
Hamour, 2006, Reversible sirolimus-associated pneumonitis after heart transplantation, J Heart Lung Transplant, 25, 241, 10.1016/j.healun.2005.08.022
David, 2007, Everolimus-associated interstitial pneumonitis in a patient with a heart transplant, Nephrol Dial Transplant, 22, 3363, 10.1093/ndt/gfm385
Exposito, 2008, Everolimus-related pulmonary toxicity in heart transplant recipients, J Heart Lung Transplant, 27, 797, 10.1016/j.healun.2008.03.016
Otton, 2009, Everolimus-associated pneumonitis in 3 heart transplant recipients, J Heart Lung Transplant, 28, 104, 10.1016/j.healun.2008.10.003
Ruiz, 2005, Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study, Transplant Proc, 37, 3833, 10.1016/j.transproceed.2005.09.127
Diekmann, 2004, Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction, Am J Transplant, 4, 1869, 10.1111/j.1600-6143.2004.00590.x
Straathof-Galema, 2006, Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism, Am J Transplant, 6, 429, 10.1111/j.1600-6143.2005.01195.x
Aliabadi, 2008, Development of Proteinuria After Switch to Sirolimus-Based Immunosuppression in Long-Term Cardiac Transplant Patients, Am J Transplant, 8, 854, 10.1111/j.1600-6143.2007.02142.x
Kovarik, 2005, Pharmacokinetic interaction between verapamil and everolimus in healthy subjects, Br J Clin Pharmacol, 60, 434, 10.1111/j.1365-2125.2005.02434.x
Kovarik, 2005, Blood concentrations of everolimus are markedly increased by ketoconazole, J Clin Pharmacol, 45, 514, 10.1177/0091270005275368
Kovarik, 2005, Effect of multiple-dose erythromycin on everolimus pharmacokinetics, Eur J Clin Pharmacol, 61, 35, 10.1007/s00228-004-0866-5
Kovarik, 2006, Everolimus drug interactions: application of a classification system for clinical decision making, Biopharm Drug Dispos, 27, 421, 10.1002/bdd.524
Caforio, 2004, Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression, Am J Transplant, 4, 962, 10.1111/j.1600-6143.2004.00434.x
Musci, 1998, Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease, Thorac Cardiovasc Surg, 46, 268, 10.1055/s-2007-1010237
Ramzy, 2005, Cardiac allograft vasculopathy: a review, Can J Surg, 48, 319
Delgado, 2007, 181: Pre-existing neoplasms and risk for malignancy after heart transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry, J Heart Lung Transplant, 26, S124, 10.1016/j.healun.2006.11.198
Tiong, 2009, A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients, Transplantation, 87, 296, 10.1097/TP.0b013e318192dd56
Data on file, Novartis Pharma AG, Basel Switzerland.